ANTHEM

** Nomura initiates coverage on Anthem Biosciences ANTH.NS with "buy," target price of 740 rupees - representing an 18% premium on last close

** Shares of ANTH rise as much as 3.6% to 651 rupees, last up ~1%

** Nomura says ANTH can sustain 17% growth in CY24–29, outpacing industry’s 13% growth in the contract research, development and manufacturing organisation segment

** Adds, co has a wider customer base and a strong "fee for service" strategy vs peers

** Anthem's stable leadership with employee attrition below peers has led strong operating performance with industry-leading profit margins and return ratios - Nomura

** Believes ANTH's key molecules' growth, new launches and capacity expansion are key positives for medium-term growth

** ANTH down 13% since listing on July 21

(Reporting by Manvi Pant)

(([email protected]; +918447554364;))

** Shares of Anthem Biosciences ANTH.NS rise 7.6% to record high of 812 rupees

** Stock marks record high intraday pct gain since debut on July 21

** Pharma co posts nearly 65% y/y rise in June-quarter consol profit; rev from ops rises nearly 60% y/y

** ANTH gains 11% since market debut

(Reporting by Rudra Pratap Singh in Bengaluru)

(([email protected]))

** Shares of India's Anthem BioSciences ANTH.NS rise 27% in trading debut to 726 rupees; shares were sold in the 540 rupees to 570 rupees price range in IPO

** Pharma co notches valuation of 408 bln rupees ($4.73 bln)

** Co's $395 million IPO, which was only a sale of shares by existing stakeholders, was fully subscribed last week

** Co - one of the leading global players in contract drugmaking and research - has made a strong debut, enjoys a niche place in the segment and leads pack of players - Shivani Nyati, Head of Wealth at Swastika Investmart

($1 = 86.2690 Indian rupees)

(Reporting by Hritam Mukherjee in Bengaluru)

(([email protected];))